NEW YORK (GenomeWeb News) – Orchid Cellmark plans to shut down its paternity testing operations in East Lansing, Mich., and move them to its facilities in Dayton, Ohio, the company said today.

The DNA testing firm plans to bring all of its US paternity operations "under one roof" in an effort to increase efficiency, Orchid CEO Thomas Bologna said in a statement today. The Dayton facility already houses some paternity testing services, and the company's call center and customer operations are based in Dayton as well, Bologna said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.